Literature DB >> 15124928

Cardioprotective effects of carvedilol on acute autoimmune myocarditis.

Zuyi Yuan1, Keisuke Shioji, Masaomi Nimata, Chiharu Kishimoto.   

Abstract

We investigated whether carvedilol protects against experimental autoimmune myocarditis (EAM) attributing to antioxidant properties. Acute EAM was induced by porcine cardiac myosin in Lewis rats. We orally administered a vehicle, various dosages of carvedilol, metoprolol, or propranolol to rats with EAM for 3 weeks. Three beta-blockers decreased heart rates to the same extent. Carvedilol, but not metoprolol or propranolol, markedly reduced the severity of myocarditis at the two different dosages. Only carvedilol decreased the myocardial protein carbonyl contents, and also decreased the myocardial thiobarbituric acid reactive substance products in rats with EAM. Accordingly, carvedilol protects against acute EAM in rats, and this superior cardioprotective effect of carvedilol to metoprolol and propranolol may be due to the antioxidant properties in addition to the hemodynamic modifications.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15124928     DOI： 10.1023/b:mcbi.0000021380.97941.78

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN： 0300-8177            Impact factor:   3.396


  16 in total

1.  Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats.

Authors:  Hiroyuki Yaoita; Atsushi Sakabe; Kazuhira Maehara; Yukio Maruyama
Journal:  Circulation       Date:  2002-02-26       Impact factor: 29.690

2.  Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids.

Authors:  P Dandona; R Karne; H Ghanim; W Hamouda; A Aljada; C H Magsino
Journal:  Circulation       Date:  2000-01-18       Impact factor: 29.690

3.  Fc receptor-mediated inhibitory effect of immunoglobulin therapy on autoimmune giant cell myocarditis: concomitant suppression of the expression of dendritic cells.

Authors:  K Shioji; C Kishimoto; S Sasayama
Journal:  Circ Res       Date:  2001-09-14       Impact factor: 17.367

4.  Effect of beta-blockers on free radical-induced cardiac contractile dysfunction.

Authors:  M Flesch; C Maack; B Cremers; A T Bäumer; M Südkamp; M Böhm
Journal:  Circulation       Date:  1999-07-27       Impact factor: 29.690

5.  Comparison of metoprolol and carvedilol pharmacology and cardioprotection in rabbit ischemia and reperfusion model.

Authors:  G Feuerstein; G L Liu; T L Yue; H Y Cheng; J P Hieble; J R Arch; R R Ruffolo; X L Ma
Journal:  Eur J Pharmacol       Date:  1998-06-26       Impact factor: 4.432

6.  A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators.

Authors:  J W Mason; J B O'Connell; A Herskowitz; N R Rose; B M McManus; M E Billingham; T E Moon
Journal:  N Engl J Med       Date:  1995-08-03       Impact factor: 91.245

7.  Carvedilol increases the production of interleukin-12 and interferon-gamma and improves the survival of mice infected with the encephalomyocarditis virus.

Authors:  Ryosuke Nishio; Tetsuo Shioi; Shigetake Sasayama; Akira Matsumori
Journal:  J Am Coll Cardiol       Date:  2003-01-15       Impact factor: 24.094

8.  Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.

Authors:  A Hjalmarson; S Goldstein; B Fagerberg; H Wedel; F Waagstein; J Kjekshus; J Wikstrand; D El Allaf; J Vítovec; J Aldershvile; M Halinen; R Dietz; K L Neuhaus; A Jánosi; G Thorgeirsson; P H Dunselman; L Gullestad; J Kuch; J Herlitz; P Rickenbacher; S Ball; S Gottlieb; P Deedwania
Journal:  JAMA       Date:  2000-03-08       Impact factor: 56.272

9.  Effect of metoprolol in acute coxsackievirus B3 murine myocarditis.

Authors:  S Rezkalla; R A Kloner; G Khatib; F E Smith; R Khatib
Journal:  J Am Coll Cardiol       Date:  1988-08       Impact factor: 24.094

10.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Authors:  M Packer; M R Bristow; J N Cohn; W S Colucci; M B Fowler; E M Gilbert; N H Shusterman
Journal:  N Engl J Med       Date:  1996-05-23       Impact factor: 91.245
View more
  1 in total

Review 1.  The clinical and diagnostic significance of anti-myosin autoantibodies in cardiac disease.

Authors:  Udi Nussinovitch; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.